Revolution Medicines Inc (RVMD)
Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on precision oncology. The company is developing targeted therapies for RAS-addicted cancers, with a research pipeline centered on RAS(ON) inhibitors and RAS companion inhibitors. Its lead programs include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), along with additional development candidates such as RMC-5127, RMC-0708, and RMC-8839. The company has also reported a phase 3 registrational trial evaluating daraxonrasib in combination with zoldonrasib in patients with first-line pancreatic ductal adenocarcinoma. Revolution Medicines was incorporated in 2014 and is headquartered in Redwood City, California. Its common stock is listed on NASDAQ under the symbol RVMD.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RVMD
|
$131.88
|
-27.2% Downside
|
Overvalued
|
$200.54
|
10.6% Upside
|
Fair
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-27.9x
|
25.5x
|
—
|
38.35 B
|
36.792 B
|
1.1%
|
91.3%
|
27.2
|
—
|
78.1%
|
